Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Report reveals lung cancer is the leading cause of cancer deaths in Florida
2.
Prostate cancer early detection system eliminates need for biopsy.
3.
Infection tied to one-fourth of deaths with lower-risk myelodysplastic syndromes
4.
November 2023, Medical Bulletin 04/.
5.
For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.
1.
Screening Strategies in Oncology: A Subspecialty Guide to Early Detection and Better Outcomes
2.
Understanding the HAS-BLED Score: What It Is and Why It Matters
3.
Autophagy: A Double-Edged Sword in Cancer Development, Immune Evasion, and Drug Resistance
4.
Precision Medicine and Genomics: Revolutionizing Healthcare Through Personalized Treatment
5.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
4.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation